Default object view. Click to create a custom template, Node ID: 114925, Object ID: 68633

Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, random...

Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial

No relation

Yes

No relation

No

18/09/2015 12:09 pm

No